Abstract: In some aspects the present disclosure provides a radiopaque, reactive copolymer comprising at least one hydrophilic polymer segment having a plurality of hydrophilic polymer segment ends, a plurality of iodinated polymer segments covalently linked to the plurality of hydrophilic polymer segment ends, and a plurality of reactive moieties covalently linked to the iodinated polymer segments. In other aspects, the present disclosure pertains to a system for forming a hydrogel composition that comprises (a) such a radiopaque, reactive copolymer and (b) a nucleophilic compound, as well as to a crosslinked reaction product of the same. In further aspects, the present disclosure pertains to a method of treatment comprising administering to a subject a mixture that comprises (a) such a radiopaque, reactive copolymer and (b) a nucleophilic compound, under conditions such that the nucleophilic compound and the radiopaque, reactive copolymer crosslink after administration.

Abstract: Compositions useful in medical procedures are described, such as separating tissue layers, e.g., submucosal tissue layers, for removal. In some examples, the compositions may include a pharmaceutically acceptable carrier fluid and one or more biocompatible materials at least partially or completely dissolved or suspended in the pharmaceutically acceptable carrier fluid. The one or more biocompatible materials may be chosen from polymers, phospholipids, nanoclays, or combinations thereof. Advantageously, the compositions may be formulated as a solution, emulsion, gel, or suspension capable of being injected into tissue.

Abstract: The present disclosure pertains to iodinated compounds that comprise at least one 2,4,6-triiodobenzene moiety in which at least one of the hydrogens at 1-, 3- and 5-positions of the 2,4,6-triiodobenzene moiety is substituted by an iodinated substituent that comprises one or more iodophenyl-containing groups. The present disclosure also pertains to compositions containing such iodinated compounds and methods of making such iodinated compounds.

Abstract: In some embodiments, the present disclosure pertains to an injectable suspension that contains radiopaque crosslinked hydrogel particles in a carrier fluid that comprises one or more types of linear hydrophilic polymers. In some embodiments, the present disclosure pertains to kits that comprise a syringe preloaded with an injectable suspension that contains radiopaque crosslinked hydrogel particles in a carrier fluid that comprises one or more types of linear hydrophilic polymers. In some embodiments, the present disclosure pertains to methods of treatment comprising injecting into a subject an injectable suspension that contains radiopaque crosslinked hydrogel particles in a carrier fluid that comprises one or more types of linear hydrophilic polymers.

Abstract: In some aspects, the present disclosure pertains to radiopaque hydrogel compositions that comprise a radiopaque polysaccharide that comprises a plurality of radiopaque moieties that are covalently linked to a carboxylic-acid-containing polysaccharide along a backbone of the carboxylic-acid-containing polysaccharide. In some aspects, the present disclosure pertains to radiopaque hydrogel compositions that comprise a carboxylate-anion-containing polysaccharide that is ionically crosslinked by multivalent cations. In other aspects, the present disclosure pertains to kits that contain such radiopaque hydrogel compositions, to methods of treatment that comprise administering such radiopaque hydrogel compositions to patients, and to methods of making such radiopaque hydrogel compositions.

Abstract: In some aspects, the present disclosure pertains to systems for forming a crosslinked polymer composition, the systems comprising (a) an iodinated multifunctional compound comprising either a plurality of electron-rich dienophile-containing moieties or a plurality of electron-poor diene-containing moieties and (b) a multifunctional multi-arm polymer comprising either a plurality of electron-poor diene-containing moieties in the case where the iodinated multifunctional compound comprises a plurality of electron-rich dienophile-containing moieties or a plurality of electron-rich dienophile-containing moieties in the case where the iodinated multifunctional compound comprises a plurality of electron-poor diene-containing moieties, wherein the crosslinked polymer composition is formed by a cycloaddition reaction occurring between the iodinated multifunctional compound and the multifunctional multi-arm polymer.

Abstract: In some aspects, the present disclosure pertains to radiopaque crosslinked hydrogel compositions that comprise a crosslinked reaction product of (a) a polyamino iodinated compound and (b) a reactive polymer that comprises a plurality of reactive groups that are reactive with the amino groups of the polyamino iodinated compound. In other aspects, the present disclosure pertains to systems for forming a hydrogel composition that comprise (a) a polyamino iodinated compound and (b) a reactive polymer that comprises a plurality of reactive groups that are reactive with the amino groups of the polyamino iodinated compound. In further aspects, the present disclosure pertains to methods of treatment using such systems.

Abstract: In some aspects, the present disclosure provides therapeutic-agent-releasing polyamino compounds that comprise a polyamino moiety that is covalently linked to a residue of a hydroxyl-substituted therapeutic agent by an ester bond. In various embodiments, such therapeutic-agent-releasing polyamino compounds are used to form therapeutic-agent-releasing hydrogels. In other aspects, the present disclosure provides therapeutic-agent-releasing polysaccharides that comprise a plurality of hydroxyl-substituted therapeutic agent residues that are covalently linked to a carboxylic-acid-containing polysaccharide along a backbone of the carboxylic-acid-containing polysaccharide.

Abstract: In some embodiments, the present disclosure pertains to multi-arm polymers having at least one polymer arm that comprises a reactive radiopaque end moiety. The radiopaque end moiety comprises a radiopaque dicarboxylic acid ester moiety containing one or more radiopaque atoms, wherein one of two ester groups of the radiopaque dicarboxylic acid ester moiety forms a link to the polymer arm, and wherein the other of the two ester groups of the radiopaque dicarboxylic acid ester moiety corresponds to a portion of a reactive electrophilic group. The present disclosure also pertains to methods of forming such multi-arm polymers and to hydrogels formed from such multi-arm polymers and a polyamino compound comprising a plurality of primary amine groups that form crosslinks with the multi-arm polymers. The present disclosure further pertains to methods and systems for forming such hydrogels and methods of treatment using such hydrogels.

Abstract: The disclosure pertains to radiopaque, unsaturated multi-arm polymers that comprise a plurality of hydrophilic polymer arms having end moieties comprising one or more radiopaque halogen groups and one or more unsaturated groups, the end moieties linked to the hydrophilic polymer arms though an ester or an amide linkage. In some embodiments, the disclosure pertains to systems for forming hydrogels, which systems comprise (a) a polyamino compound and (b) a radiopaque, unsaturated multi-arm polymer that comprises a plurality of hydrophilic polymer arms having end moieties comprising one or more radiopaque halogen groups and one or more unsaturated groups, the end moieties linked to the hydrophilic polymer arms though an ester or an amide linkage, wherein the one or more unsaturated groups are reactive with the amino groups of the polyamino compound. Other embodiments pertain to methods of treatment using such systems and to hydrogels formed from such systems.

Abstract: In some aspects, the present disclosure pertains to systems for forming a hydrogel that comprise (a) an iodinated polyamino compound and (b) a reactive multi-arm polymer that comprises a plurality of hydrophilic polymer arms having unsaturated end groups that are reactive with amino groups of the iodinated polyamino compound. Other aspects of the present disclosure pertain to medical hydrogels that are formed by crosslinking the iodinated polyamino compound and the reactive multi-arm polymer of such systems. Further aspects of the present disclosure pertain to medical procedures that can be performed using such systems.

Abstract: The present disclosure relates to radiopaque PVA polymers where the PVA has a first pendant group and a second pendant group, wherein the first pendant group comprises a first phenyl group bearing 1 to 5 iodine atoms, and the second pendant group comprises either (a) a second phenyl group bearing 1 to 3 substituents selected from the group W and optionally 1 to 4 iodine substituents, the group(s) W and the optional iodines being the sole substituents of the second phenyl group. Each W is selected from —OH, —COOH, —SO3H, —OPO3H2, —O—(C1-4alkyl), —O—(C1-4alkyl)OH, —O—(C1-4alkyl)R2, —O—(C2H5O)qR1 —(C?O)—O— C1-4alkyl and —O—(C?O)C1-4alkyl; wherein R1 is H or C1-4 alkyl; R2 is —COOH, —SO3H, or —OPO3H2; q is an integer from 1 to 4; wherein the group W may be in the form of a pharmaceutically acceptable salt; or (b) a pyridyl group; which is optionally in the form of a pyridinium ion.

Abstract: The present disclosure relates to radiopaque PVA polymers where the PVA has a first pendant group and a second pendant group, wherein the first pendant group comprises a first phenyl group bearing 1 to 5 iodine atoms, and the second pendant group comprises either (a) a second phenyl group bearing 1 to 3 substituents selected from the group W and optionally 1 to 4 iodine substituents, the group(s) W and the optional iodines being the sole substituents of the second phenyl group. Each W is selected from —OH, —COOH, —SO3H, —OPO3H2, —O—(C1-4alkyl), —O—(C1-4alkyl)OH, —O—(C1-4alkyl)R2, —O—(C2H5O)qR1—(C?O)—O—C1-4alkyl and —O—(C?O)C1-4alkyl; wherein R1 is H or C1-4 alkyl; R2 is —COOH, —SO3H, or —OPO3H2; q is an integer from 1 to 4; wherein the group W may be in the form of a pharmaceutically acceptable salt; or (b) a pyridyl group; which is optionally in the form of a pyridinium ion.

Abstract: In some embodiments, the present disclosure pertains to liquid compositions for medical use that comprise (a) a polymer, a monomer, a macromonomer, or a combination of any two or all three of the foregoing and (b) spherical metallic particles, which may comprise, for example, tantalum, tungsten, rhenium, niobium, molybdenum, and alloys of the foregoing. In some embodiments, the present disclosure pertains to medical methods that comprise administering such liquid compositions to a patient. In some embodiments, the present disclosure pertains to use of such liquid compositions as liquid embolics, fiducial markers, tissue-spacing materials, or therapeutic agent depots. In some embodiments, the present disclosure pertains to medical devices that comprise coatings formed from such liquid compositions.

Abstract: The present disclosure pertains to iodinated compounds that comprise at least one 2,4,6-triiodobenzene moiety in which at least one of the hydrogens at 1-, 3- and 5-positions of the 2,4,6-triiodobenzene moiety is substituted by an iodinated substituent that comprises one or more iodophenyl-containing groups. The present disclosure also pertains to compositions containing such iodinated compounds and methods of making such iodinated compounds.

Abstract: The present disclosure relates to radiopaque PVA polymers where the PVA has a first pendant group and a second pendant group, wherein the first pendant group comprises a first phenyl group bearing 1 to 5 iodine atoms, and the second pendant group comprises either (a) a second phenyl group bearing 1 to 3 substituents selected from the group W and optionally 1 to 4 iodine substituents, the group(s) W and the optional iodines being the sole substituents of the second phenyl group. Each W is selected from —OH, —COOH, —SO3H, —OPO3H2, —O—(C1-4alkyl), —O—(C1-4alkyl)OH, —O—(C1-4alkyl)R2, —O—(C2H5O)qR1—(C?O)—O—C1-4alkyl and —O—(C?O)C1-4alkyl; wherein R1 is H or C1-4 alkyl; R2 is —COOH, —SO3H, or —OPO3H2; q is an integer from 1 to 4; wherein the group W may be in the form of a pharmaceutically acceptable salt; or (b) a pyridyl group; which is optionally in the form of a pyridinium ion.